New transparency rules which require the registration of a clinical trial before any results of the trial become available are a response to public pressure. The patenting situation in the U.S. does not appear to have severely worsened since the introduction of the transparency rules. In Europe, however, revised transparency regulations have negatively impacted investigators’ ability to protect clinical trial-related inventions by patents. (